R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine [VCR], and prednisolone) is the standard of care for previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
However, some DLBCL survivors experience long-lasting VCR-related peripheral neuropathy (PN).
VCR dose is usually reduced based on PN severity, but inconsistent results have been reported regarding the effect of VCR dose reduction on the prognosis of patients with DLBCL.
To evaluate the clinical impact of the relative dose intensity (RDI) of VCR (RDI
